The state of Florida currently has 200 active clinical trials seeking participants for Breast Cancer research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371
Recruiting
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Register for Updates
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT04787042
Recruiting
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Register for Updates
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752
Recruiting
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: BRCR Global, Plantation, Florida
Conditions: Non Small Cell Lung Cancer, Breast Cancer
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: The Watson Clinic, Lakeland, Florida
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
HIIT Following Breast Cancer Chemotherapy
NCT05913713
Recruiting
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training... Read More
Gender:
FEMALE
Ages:
Between 18 years and 85 years
Trial Updated:
10/22/2024
Locations: Integrative Cardiovascular Physiology Laboratory, University of Florida, Gainesville, Florida
Conditions: Breast Cancer
Register for Updates
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01042379
Recruiting
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Register for Updates
Precise Oncology Interventions in Nutrition and Training (OnPoint)
NCT06534918
Recruiting
The purpose of this study is to see if survivors of breast, prostate, or colorectal cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer
Register for Updates
Prolonged Overnight Fasting And/or Exercise on Fatigue and Other Patient Reported Outcomes in Women with Hormone Receptor Positive Advanced Breast Cancer
NCT06123988
Recruiting
The purpose of this study is to test if four different programs (prolonged overnighting fasting alone, exercise alone, a combination of prolonged overnight fasting and exercise, or general health education sessions alone) can reduce fatigue in women with advanced or metastatic breast cancer who are receiving a medication called a cyclin-dependent kinases-4 and 6 (CDK4/6) inhibitor.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: University of Miami, Miami, Florida
Conditions: HER2-positive Breast Cancer, Advanced Breast Cancer
Register for Updates
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
NCT05508906
Recruiting
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: OP-1250 in combination with everolimus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Advent Health Hematology and Oncology, Orlando, Florida
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Breast Cancer
Register for Updates
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT05721248
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Mayo Clinical Hospital Florida, Jacksonville, Florida
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT04553770
Recruiting
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Orlando Health, Inc. d/b/a Orlando Health UF Health Center, Orlando, Florida
Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Register for Updates
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT05074290
Recruiting
Patients with breast cancer are commonly treated with taxane chemotherapy. Some very common side effects of taxanes, such as anemia and peripheral neuropathy, are often as not well addressed during treatment, resulting in dose reductions, dose delays and early discontinuation (collectively called relative dose intensity) of these chemotherapy agents in 15-80 % of patients on these drugs. This reduction in relative dose intensity (RDI) results in worse clinical outcomes such as progression free a... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/09/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Breast Cancer
Register for Updates